

APR 30 2003

GROUP 1600

01702.401600

PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
GUSTAV GAUDERNACK, ET AL.	:	Examiner: Christopher Nichols, Ph.D.
Application No.: 09/674,913	)	
Filing Date: May 25, 2001	:	Group Art Unit: 1647
Int'l Appl. No.: PCT/NO99/00141	)	
Int'l Appl. Filing Date: April 30, 1999	:	
For: FRAMESHIFT MUTANTS OF	)	
BETA-AMYLOID PRECURSOR	:	
PROTEIN AND UBIQUITIN-B	)	
AND THEIR USE	:	

SUPPLEMENTAL DECLARATION UNDER 37 C.F.R §1.132  
OF PROF. GUSTAV GAUDERNACK

I, Gustav Gaudernack, of Sandvika, Norway, do hereby declare as follows:

1. I am the Gustav Gaudernack who signed the Declaration dated April 2, 2003, regarding the above-identified U.S. patent application. I offer this Supplemental Declaration as further explanation of the test results that are reported in Paragraph 5 of my earlier Declaration.
2. Figure 1 shows that Sequence ID No.1, a peptide fragment of the mutant  $\beta$ -amyloid protein unique to Alzheimer's disease cells, stimulated the proliferation of T cells from the mononuclear cell fraction isolated from the peripheral blood of an Alzheimer's

disease patient. Subsequent cloning has shown that the responding T cells are of the T-helper phenotype. Figure 2 shows that of the five peptides (Sequence ID Nos. 1, 3, 5, 6 and 10), the peptide having Sequence ID No.1 induced the most T cell proliferation. As the T cell response observed is a "memory type" of immune response, these results demonstrate that Sequence ID No.1 is capable of stimulating the proliferation of memory T lymphocytes that are specific for a peptide present in patients with Alzheimer's disease cells bearing the mutant  $\beta$ -amyloid protein fragment.

3. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed by me to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of any patent that might issue on the above-identified application.

Gustav Gaudernack  
Gustav Gaudernack

28.04.03  
Date